A detailed history of Graham Capital Management, L.P. transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Graham Capital Management, L.P. holds 42,186 shares of ZNTL stock, worth $132,042. This represents 0.0% of its overall portfolio holdings.

Number of Shares
42,186
Previous 11,465 267.95%
Holding current value
$132,042
Previous $46,000 234.78%
% of portfolio
0.0%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.9 - $4.57 $89,090 - $140,394
30,721 Added 267.95%
42,186 $154,000
Q2 2024

Aug 14, 2024

BUY
$4.09 - $16.13 $46,891 - $184,930
11,465 New
11,465 $46,000
Q3 2023

Nov 22, 2023

BUY
$19.63 - $28.29 $208,078 - $299,874
10,600 New
10,600 $212,000

Others Institutions Holding ZNTL

About Zentalis Pharmaceuticals, Inc.


  • Ticker ZNTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,983,600
  • Market Cap $178M
  • Description
  • Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...
More about ZNTL
Track This Portfolio

Track Graham Capital Management, L.P. Portfolio

Follow Graham Capital Management, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Graham Capital Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Graham Capital Management, L.P. with notifications on news.